Pharmacological properties of a new beta-blocking agent (1-isopropylamino-3-(2-methyl-3-nitrophenoxy)-propan-2-ol).
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000633:toxicity; D000779:Anesthetics, Local / Q000494:pharmacology / Q000633:toxicity; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000633:toxicity; D002415:Cats; D004353:Drug Evaluation, Preclinical; D005260:Female; D006168:Guinea Pigs; D006339:Heart Rate / Q000187:drug effects; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D009574:Nitro Compounds / Q000494:pharmacology / Q000633:toxicity; D010647:Phenyl Ethers / Q000494:pharmacology / Q000633:toxicity; D011412:Propanolamines / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats
D000319:Adrenergic beta-Antagonists; D000779:Anesthetics, Local; D000889:Anti-Arrhythmia Agents; D009574:Nitro Compounds; D010647:Phenyl Ethers; D011412:Propanolamines